主页 > 医学动态 >
【medical-news】＂肌肉＂蛋白驱动前列腺癌进程
Researchers at the Johns Hopkins Kimmel Cancer Center have for the first time implicated the muscle protein myosin VI in the development of prostate cancer and its spread.
In a series of lab studies with human prostate cancer cells, the Hopkins scientists were surprised to find overproduction of myosin VI in both prostate tumor cells and precancerous lesions. When the scientists genetically altered the cells to "silence" myosin VI, they discovered the cells were less able to invade in a test tube.
"Our results suggest that myosin VI may be critical in starting and maintaining the malignant properties of the majority of human prostate cancers diagnosed today," says Angelo M. De Marzo, M.D., Ph.D., a study coauthor and associate professor of pathology, urology and oncology.
The Hopkins work, published in the November issue of the American Journal of Pathology, has potential value for better ways to diagnose the disease, treat and track the effects of drugs and surgery. "Targeting myosin VI represents a promising new approach that could lead eventually new approaches to treating the disease," says Jun Luo, Ph.D., senior author of the paper and assistant professor of urology.
Myosins are a class of 40 motor proteins that power cell movement and muscle contractions. Normally, as they work, myosins slide in a single direction along the threads of a protein called actin. But myosin VI moves against the grain, and it does not function as a classical "muscle" protein.
Using a DNA microarray to study all of the genes in 59 samples of benign or cancerous prostate tissue from patients at Johns Hopkins, the researchers found the malignant samples showed a 3.7-fold higher expression of myosin VI as compared to normal samples, and a 4.6-fold increase as compared to the samples from patients with enlarged prostate.
Next, the researchers hunted for myosin VI in 240 prostate tissue samples, discovering overproduction early in the development of prostate cancer in such pre-tumor conditions as high-grade prostatic intraepithelial neoplasia (PIN) and proliferative inflammatory atrophy.
Finally, when they altered some cancerous cells by knocking down their myosin VI protein, the cancer cells not only were less able to spread around, but also showed 10 times the amount of a tumor suppressor called thioredoxin-interacting protein (TXNIP).
Prostate cancer, which affects one in nine American men over the course of their lives, is mainly diagnosed by needle biopsy of the prostate gland after a blood test shows an increased level of prostate-specific antigen (PSA). While the PSA test is now widespread and provides many men with early diagnosis and better chance of a cure, says Luo, it may not be sensitive or specific enough to pinpoint the existence of cancer. Using myosin VI or other factors, it may be possible, Luo says, to create a laboratory test to identify high or low levels in urine or blood samples, and this might aid in the detection of prostate cancer. Myosin VI also has been shown to be associated with ovarian cancer. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 "肌肉"蛋白驱动前列腺癌进程
'Muscle' protein drives prostate cancer
Researchers at the Johns Hopkins Kimmel Cancer Center have for the first time implicated the muscle protein myosin VI in the development of prostate cancer and its spread.
Johns Hopkins Kimmel癌症中心的研究员第一次指出了肌肉蛋白肌球蛋白VI在前列腺癌发展和扩散中的作用。
In a series of lab studies with human prostate cancer cells, the Hopkins scientists were surprised to find overproduction of myosin VI in both prostate tumor cells and precancerous lesions. When the scientists genetically altered the cells to "silence" myosin VI, they discovered the cells were less able to invade in a test tube.
在一系列对人体前列腺癌细胞的实验室研究中，Hopkins的科学家惊讶的发现肌球蛋白VI在前列腺肿瘤细胞和癌前期突变中都有过度表达。当科学家从遗传学上改变细胞使肌球蛋白VI“沉默”，他们发现在试管中的细胞没有侵入性。
"Our results suggest that myosin VI may be critical in starting and maintaining the malignant properties of the majority of human prostate cancers diagnosed today," says Angelo M. De Marzo, M.D., Ph.D., a study coauthor and associate professor of pathology, urology and oncology.
“我们的结果暗示，肌球蛋白VI在启动和维持人体前列腺癌的恶化中起关键作用，” Angelo M. De Marzo说。Angelo M. De Marzo是医学和药学博士，该研究的合作者，病理学，泌尿学和肿瘤学副教授。
The Hopkins work, published in the November issue of the American Journal of Pathology, has potential value for better ways to diagnose the disease, treat and track the effects of drugs and surgery. "Targeting myosin VI represents a promising new approach that could lead eventually new approaches to treating the disease," says Jun Luo, Ph.D., senior author of the paper and assistant professor of urology.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-21 17:11
医学,生命科学网